Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.
canakinumab 180 MG Injection [Ilaris]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic… Expand
Review
2015
Review
2015
Subcutaneous canakinumab (Ilaris®) is a human monoclonal anti-human interleukin (IL)-1β antibody of the immunoglobulin G1… Expand
2014
2014
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with… Expand
Review
2013
Review
2013
Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a… Expand
Review
2013
Review
2013
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs… Expand
2013
2013
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been… Expand